Compugen’s COM503 Advances with FDA Nod and Gilead Deal

Compugen (CGEN) has released an update.

Compugen Ltd. has announced FDA clearance for their Phase 1 trial of COM503, a potential new cancer treatment for solid tumors, slated to begin in Q4 2024. This clearance has resulted in a $30 million milestone payment from Gilead Sciences, as part of a larger licensing agreement that could ultimately be worth up to $848 million. The company is optimistic about the antibody’s unique approach to harnessing cytokine biology and is well-funded to continue development activities into 2027.

For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.